No Data
UCB, Biogen Present Results From PHOENYCS GO Study
Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint
UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham Downgrades Biogen on Slow Growth of Alzheimer's Drug